KPTI Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc (KPTI) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $116.3K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Abate Kristin | Chief Accounting Officer | Sell | 19 | $2.02 | $38 | 23,782 −0.1% of holding | |
| Poulton Stuart | EVP, Chief Development Officer | Sell | 189 | $7.10 | $1.3K | 94,632 −0.2% of holding | |
| Paulson Richard A. | President and CEO | Sell | 2,203 | $9.50 | $20.9K | 269,747 −0.8% of holding | |
| Rangwala Reshma | EVP & Chief Medical Officer | Sell | 408 | $9.50 | $3.9K | 56,829 −0.7% of holding | |
| Poulton Stuart | EVP, Chief Development Officer | Sell | 403 | $9.50 | $3.8K | 94,821 −0.4% of holding | |
| Cheng Sohanya Roshan | EVP & Chief Commercial Officer | Sell | 324 | $9.50 | $3.1K | 107,940 −0.3% of holding | |
| Mano Michael | EVP, CLO&Secretary | Sell | 266 | $9.50 | $2.5K | 94,398 −0.3% of holding | |
| Abate Kristin | Chief Accounting Officer | Sell | 53 | $9.50 | $504 | 23,801 −0.2% of holding | |
| Rangwala Reshma | EVP & Chief Medical Officer | Sell | 449 | $8.94 | $4.0K | 56,290 −0.8% of holding | |
| Paulson Richard A. | President and CEO | Sell | 12,361 | $9.41 | $116.3K | 267,030 −4.4% of holding | |
| Poulton Stuart | EVP, Chief Development Officer | Sell | 5,101 | $9.41 | $48.0K | 94,328 −5.1% of holding | |
| Rangwala Reshma | EVP & Chief Medical Officer | Sell | 5,066 | $9.41 | $47.7K | 56,739 −8.2% of holding | |
| Cheng Sohanya Roshan | EVP & Chief Commercial Officer | Sell | 4,604 | $9.41 | $43.3K | 107,317 −4.1% of holding | |
| Mano Michael | EVP, CLO&Secretary | Sell | 3,526 | $9.41 | $33.2K | 93,964 −3.6% of holding | |
| Abate Kristin | Chief Accounting Officer | Sell | 559 | $9.41 | $5.3K | 22,063 −2.5% of holding | |
| Poulton Stuart | EVP, Chief Development Officer | Sell | 378 | $8.63 | $3.3K | 99,429 −0.4% of holding | |
| Macomber Lori | EVP, CFO & Treasurer | Sell | 1,626 | $6.30 | $10.2K | 85,105 −1.9% of holding | |
| Abate Kristin | Chief Accounting Officer | Sell | 50 | $7.03 | $352 | 22,622 −0.2% of holding | |
| Abate Kristin | Chief Accounting Officer | Sell | 265 | $5.96 | $1.6K | 22,580 −1.2% of holding | |
| Abate Kristin | Chief Accounting Officer | Sell | 362 | $6.30 | $2.3K | 10,046 −3.5% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.